# Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

> **NCT00002070** · PHASE3 · COMPLETED · sponsor: **Schering-Plough**

## Conditions studied

- Cytomegalovirus Retinitis
- HIV Infections

## Interventions

- **DRUG:** Sargramostim
- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT00002070
- **Lead sponsor:** Schering-Plough
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002070, "Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*